ClinicalTrials.gg
Not yet recruitingNCT07302516Updated Dec 24, 2025

Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma

A Phase 3 interventional study of tezepelumab (Arm1&Arm2) in Asthma, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
636
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing tezepelumab in Asthma — 7 open to participants now, 8 under way, 5 of them phase 3. tezepelumab · Asthma.

Planned enrollment
3rd of 28
636 · median 121
Started
2025
with 2 others
Phase 3
16 of 28
4 open now
Registered
27th of 28
by date
Lead sponsor
1 of 28
Qilu Pharmaceutical Co., Ltd.

Among the 28 studies testing tezepelumab in Asthma, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2025, is one of 16 in phase 3, and was the 27th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 28 studies testing tezepelumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About tezepelumab

tezepelumab: first FDA approval 2021 (TEZSPIRE), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing tezepelumab in Asthma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the efficacy and safety of QL2302 and Tezspire® in patients with uncontrolled severe asthma. The main questions it aims to answer are:

  • if the efficacy of QL2302 and Tezspire® are similar
  • if the safety of QL2302 and Tezspire® are similar

Participants will be randomised to QL2302 or Tezspire® group and asked to receive one injection of QL2302 or Tezspire® subcutaneously every four weeks till Week 48, which means participants will receive a total of 13 injections. And be observed for another 12 weeks after the end of treatment.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-80 year of age
  2. Body weight ≥40 kg
  3. Diagnosed with asthma ≥12 months
  4. Received a total daily dose of medium/high dose of ICS for more than 3 months steadily
  5. At least one additional maintenance asthma controller medication is required according to standard practice of care and must be documented for at least 3 months.
  6. Morning pre-BD \<80% but ≥35% predicted normal
  7. Evidence of asthma as documented by reversibility test or change of PEF.
  8. Documented history of at least 1 asthma exacerbation events within 12 months.
  9. ACQ-5 score ≥1.5 at screening and on day of randomization

Exclusion criteria

Exclusion Criteria:

  1. Pulmonary disease other than asthma.
  2. History of cancer within 5 years except those cured.
  3. History of a infection within 4 weeks.
  4. Current smokers or participants with smoking history ≥10 pack-yrs.
  5. History of chronic alcohol or drug abuse within 12 months.
  6. Positive , C or infection.
  7. Pregnant or breastfeeding.
  8. History of anaphylaxis following any biologic therapy.
  9. Participant received tezepelumab or other TSLP antibody priorly.
  10. Participant received bronchial thermoplasty within 12 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
636 participants (estimated)

Study arms

  • Experimental
    QL2302

    Biological: tezepelumab (Arm1&Arm2)

  • Active comparator
    Tezspire®

    Biological: tezepelumab (Arm1&Arm2)

Interventions

06

What researchers measure

Primary outcomes

  1. Primary endpoint :

    Annualized Asthma Exacerbation Rate (AAER)

    Time frame: 52 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Dec 2028, 36 months later.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 36 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 24, 2025
StartEst.
Dec 25, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07302516
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Dec 25, 2025 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Dec 24, 2025

Study contacts

Min Zhang, PhD
Contact
13482345145@163.com
13482345145

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion